Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'
- PMID: 33674263
- DOI: 10.1136/annrheumdis-2021-219890
Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'
Keywords: autoimmunity; immune system diseases; inflammation; therapeutics.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday et al.Ann Rheum Dis. 2023 May;82(5):e105. doi: 10.1136/annrheumdis-2021-219919. Epub 2021 Mar 4. Ann Rheum Dis. 2023. PMID: 33674265 No abstract available.
Comment on
-
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.Ann Rheum Dis. 2021 Jan;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398. Epub 2020 Nov 6. Ann Rheum Dis. 2021. PMID: 33158881 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
